Alzheon, Inc. is a biotechnology company dedicated to developing innovative treatments for Alzheimer's disease. The company focuses on creating therapeutics that aim to slow or halt the progression of Alzheimer's and potentially prevent the onset of clinical symptoms.
ALZ-801/valiltramiprosate is an oral small molecule inhibitor designed to target the neurotoxic amyloid oligomers, which are believed to play a key role in the development and progression of Alzheimer's disease.
It addresses the need for easily accessible Alzheimer's treatments that can slow disease progression and potentially prevent clinical symptoms.
Lack of effective and accessible treatment options that can slow disease progression or prevent onset